You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR INFLUENZA VACCINE, ADJUVANTED


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for influenza vaccine, adjuvanted

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00133471 ↗ Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 1/Phase 2 2005-03-01 The purpose of this study is to compare the body's reactions and immune responses after receiving different strengths of a H9N2 influenza virus vaccine with and without an adjuvant given into the arm muscle. Study participants will include up to 96 healthy adults, ages 18-34. The 4 dosages of the experimental H9N2 vaccine to be tested in this study are the following: 3.75, 7.5, 15, and 30-mcg (with and without MF59 adjuvant). Participants will be vaccinated on Days 0 and 28. Participants will record any vaccine side effects in a diary for 7 days following each vaccination. Participants will return to the clinic on days 2 and 7 after vaccination. Blood samples will be collected 7 days following each vaccination. Serum and nasal wash specimens will be collected before each vaccination and 4 weeks after injections (0, 4, and 8 weeks). Participants will be involved in study related procedures for up to 8 months.
NCT00296634 ↗ H5 Vaccine Alone or With Adjuvant in Healthy Adults Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 1/Phase 2 2006-03-01 This randomized, controlled, double-blinded, dose-ranging, Phase I-II study in 600 healthy adults, 18 to 49 years old, is designed to investigate the safety, reactogenicity, and dose-related immunogenicity of an investigational inactivated influenza A/H5N1 virus vaccine when given alone or combined with aluminum hydroxide. A secondary goal is to guide selection of vaccine dosage levels for expanded Phase II trials based on reactogenicity and immunogenicity profiles. This dose optimization will be applied to both younger and older subject populations in subsequent studies. Subjects who meet the entry criteria for the study will be enrolled at one of 4 study sites and will be randomized into one of 8 groups to receive 2 doses of influenza A/H5N1 vaccine containing 3.75, 7.5, 15, or 45 mcg of HA with or without aluminum hydroxide adjuvant by intramuscular injection. Participants may be involved in study related procedures for up to 8 months.
NCT00912496 ↗ Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59 Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 1 2010-06-01 This research will study safety and the body's immune (defense system) responses, including anti-H5 flu antibodies (the body's protective proteins found in the blood), to an inactivated influenza "H5" bird flu, virus vaccine. Participants will be assigned by chance to receive the vaccine injections with and without an adjuvant, (substance that can improve vaccine effectiveness so less vaccine may be used) MF59, or placebo (inactive substance). Five different vaccine dose strengths will be evaluated. About 735 healthy participants, ages 18-49 will be asked to take part in this study. Study procedures include physical exam, blood sampling, and use of a memory aid. Volunteers will participate for up to 13 months.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for influenza vaccine, adjuvanted

Condition Name

Condition Name for influenza vaccine, adjuvanted
Intervention Trials
Influenza 12
Avian Influenza 4
Influenza Immunisation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for influenza vaccine, adjuvanted
Intervention Trials
Influenza, Human 16
Influenza in Birds 6
Sarcoidosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for influenza vaccine, adjuvanted

Trials by Country

Trials by Country for influenza vaccine, adjuvanted
Location Trials
United States 41
Philippines 5
Australia 4
South Africa 2
United Kingdom 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for influenza vaccine, adjuvanted
Location Trials
Texas 6
Maryland 5
Ohio 5
Tennessee 4
Iowa 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for influenza vaccine, adjuvanted

Clinical Trial Phase

Clinical Trial Phase for influenza vaccine, adjuvanted
Clinical Trial Phase Trials
Phase 4 3
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for influenza vaccine, adjuvanted
Clinical Trial Phase Trials
Completed 12
Active, not recruiting 3
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for influenza vaccine, adjuvanted

Sponsor Name

Sponsor Name for influenza vaccine, adjuvanted
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 11
Seqirus 2
US Department of Veterans Affairs 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for influenza vaccine, adjuvanted
Sponsor Trials
NIH 12
Other 8
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.